|
|
||||||||
European Journal of Cardio-Thoracic Surgery, Vol 9, 553-556, Copyright © 1995 by European Association for Cardio-thoracic Surgery
R Dhillon, GA Pearson, RK Firmin, KC Chan and R Leanage
Certain forms of congenital heart disease (CHD) confer a high risk for the
development of severe pulmonary hypertension before and after corrective
cardiac surgery. Extracorporeal membrane oxygenation (ECMO) has theoretical
benefits in the treatment of this complication in that it assures
oxygenation, corrects acid-base balance and provides haemodynamic support
at the same time as allowing lung rest from ventilation. We examined our
experience of the 117 children and neonates supported with ECMO between
November 1989 and July 1993. Of these, five received support for critical
pulmonary hypertension associated with congenital heart disease. They
comprised three who had undergone surgical repair of CHD, one whose total
anomalous pulmonary venous drainage was diagnosed and corrected whilst on
ECMO and one neonate with functional pulmonary atresia. Pulmonary artery
pressure (PAP) was estimated by Doppler echocardiography in all patients
and confirmed invasively in two. The median systolic PAP was 46 (range 42-
65) mmHg prior to ECMO. The median ratio of pulmonary to systemic arterial
pressure (PAP/SAP) was 0.75 (0.70-0.92). Following ECMO of 16- 120 h
duration, the median systolic PAP was 34 (30-49) mmHg with PAP/SAP 0.50
(0.35-0.60). All patients survived and there were no complications related
to ECMO. Extracorporeal membrane oxygenation is an effective treatment in
critical pulmonary hypertension and should be considered in all patients in
whom this is refractory to conventional measures.
ARTICLES
Extracorporeal membrane oxygenation and the treatment of critical pulmonary hypertension in congenital heart disease
Department of Paediatric Cardiology, Glenfield Hospital, Leicester, UK.
This article has been cited by other articles:
![]() |
B. Alsoufi, I. Shen, T. Karamlou, C. Giacomuzzi, G. Burch, M. Silberbach, and R. Ungerleider Extracorporeal Life Support in Neonates, Infants, and Children After Repair of Congenital Heart Disease: Modern Era Results in a Single Institution Ann. Thorac. Surg., July 1, 2005; 80(1): 15 - 21. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. O'Blenes, S. Fischer, B. McIntyre, S. Keshavjee, and M. Rabinovitch Hemodynamic unloading leads to regression of pulmonary vascular disease in rats J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0279 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Langley, S. V. Sheppard, V. T. Tsang, J. L. Monro, and R. K. Lamb When is extracorporeal life support worthwhile following repair of congenital heart disease in children? Eur. J. Cardiothorac. Surg., May 1, 1999; 13(5): 520 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Goldman, R. E. Delius, J. E. Deanfield, M. R. de Leval, P. E. Sigston, and D. J. Macrae Nitric Oxide Might Reduce the Need for Extracorporeal Support in Children With Critical Postoperative Pulmonary Hypertension Ann. Thorac. Surg., September 1, 1996; 62(3): 750 - 755. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |